FDA approves Sarepta gene therapy

The latest stories trending on MedCity News.

Editor's Pick

Top Story FDA Approves Sarepta Gene Therapy, But Only After Top FDA Official Bucks Agency Staff FDA reviewers concluded the data for Sarepta Therapeutics' Elevidys were insufficient to show efficacy in the rare muscle disorder Duchenne muscular dystrophy. Peter Marks, the agency's top biologics official, reviewed the same data and reached a different conclusion. Sponsored The Value of Differential Diagnosis: A Catalight White Paper Presented by Catalight Learn how Catalight is working towards expanding care while simultaneously improving quality, accessibility, and affordability for families who need I/DD and ASD care. Download the white paper here!

Featured News

Knownwell Acquires Competitor to Expand Access to Comprehensive Obesity Care Knownwell acquired one of its competitors, just six months after announcing its $20 million Series A funding round. The startup, which provides hybrid primary care and metabolic health treatment, bought Alfie Health, an online obesity management clinic with an AI platform that generates personalized recommendations for weight management. What's Missing from Value-Based Care Convos, According to Providence Health Plan's CEO In a recent interview, Don Antonucci, president and CEO of Providence Health Plan, spoke about how the industry needs to improve value-based care. AI-Driven Breakthroughs: Transforming Patient Care through Research Consulting This not only enhances the quality of care and patient satisfaction but also optimizes operational efficiency.

Resources

MedCity FemFwd: What Needs To Happen to Improve Preeclampsia Rates? In this episode, we're joined by John Auerbach, senior vice president of federal health at consulting firm ICF. He discusses rising preeclampsia rates and how stakeholders need to act. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe